Market Cap | 47.40M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -228k | Forward P/E | -0.28 | EPS next Y | - | 50D Avg Chg | -11.00% |
Sales | 6.65M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 5.00% |
Dividend | N/A | Price/Book | 1.03 | EPS next 5Y | - | 52W High Chg | -47.00% |
Recommedations | 3.00 | Quick Ratio | 3.54 | Shares Outstanding | 60.75M | 52W Low Chg | 160.00% |
Insider Own | - | ROA | -30.14% | Shares Float | 27.99M | Beta | 2.13 |
Inst Own | 7.65% | ROE | -0.98% | Shares Shorted/Prior | 17.79K/94.95K | Price | 0.78 |
Gross Margin | 100.00% | Profit Margin | -3.43% | Avg. Volume | 150,691 | Target Price | 2.96 |
Oper. Margin | -408.41% | Earnings Date | - | Volume | 3,205 | Change | 1.30% |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Cowen & Co. | Outperform | Dec 5, 17 |